STAT
Transcription factors (TFs) are key cellular components that control the first step of gene expression, the transcription of DNA into RNA sequences. By ensuring the correct expression of specific genes, the transcriptional regulatory system plays a central part in controlling many biological processes, ranging from cell cycle progression and maintenance of intracellular metabolic and physiological balance, to cellular differentiation and developmental time courses. TFs may be constitutively active or conditionally active. The most common classification of TFs is based on the structure of their DNA-binding domains. Grouping TFs by structural domain has been extremely useful in uncovering how they recognize and bind specific DNA sequences, as well as providing insights into their evolutionary histories. Moreover, in some instances the DNA-binding domain provides clues to their function[1]. A comprehensive classification recognizes four superfamilies with well-defined structural homology: basic domains TFs (1), Zinc-coordinating domains TFs (2), helix-turn-helix (HTH) domains TFs (3), and beta-scaffold domains with Minor Groove Contacts TFs (4). Additionally, a fifth family of orphan TFs exists for which no superclass assignment can be done yet because of lack of structural information[2].
This superfamily of transcription factors with β-scaffold DNA-binding domains with minor groove contacts comprises 11 subclasses: RHR, STAT, p53, MADS box, β-Barrel α-helix transcription factors, TATA binding proteins, HMG-box, Heteromeric CCAAT factors, grainyhead, Cold-shock domain factors, and Runt[2]. Late SV40 Factor (LSF), also known as alpha-globin transcription factor CP2 (TFCP2), functions as part of the SSP(stage selector protein) complex, and binds a variety of cellular and viral promoters including fibrinogen, alpha-globin, SV40 and HIV-1 promoters[3].
[1] J.M. Vaquerizas et al. A census of human transcription factors: function, expression and evolution. Nat. Rev. Genetics 2009, 10, 252-263.
[2] P. Stegmaier, A.E. Kel, E. Wingender. SystematicDNA-binding domain classification of transcription factors. Genome Inform. 2004, 15, 276-286.
[3] P.K. Santhekadur et al. The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. Am. J. Cancer Res. 2012, 2, 269-285.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
3834 | Alantolactone | STAT3 inhibitor; NLRP3 inhibitor | €90.00 | |
1992 | AS 1517499 | Potent and selective STAT6 inhibitor | €130.00 | |
3786 | BP-1-102 | Orally bioavailable STAT3 inhibitor | €90.00 | |
2489 | Brassinin | Dual IDO1/STAT3 inhibitor with antifungal and anticancer activity | €75.00 | |
3457 | Fludarabine | Inhibitor of DNA synthesis; STAT-1 activation inhibitor | €50.00 | |
3270 | Lj-1-60 | Fyn inhibitor targeting the Fyn/Stat3 pathway | €90.00 | |
2517 | Napabucasin | Oral first-in-class cancer stemness inhibitor that works by targeting STAT3 | €105.00 | |
2488 | Piperlongumine | Natural alkaloid with potent cytotoxic activity | €65.00 | |
2313 | S3I 201 | Potent, cellular STAT3 inhibitor | €90.00 | |
2731 | STAT5 Inhibitor 1 [285986-31-4] | Nonpeptidic small-molecule inhibitor of STAT5 activation | €90.00 | |
2314 | Stattic | Nonpeptidic small-molecule inhibitor of STAT3 activation, dimerization, and nuclear translocation | €50.00 | |
2316 | WP 1066 | Potent JAK2 and STAT3 inhibitor and downregulator of antiapoptotic proteins | €95.00 |